Leerink Partners Maintains Outperform on Tango Therapeutics, Raises Price Target to $55
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Andrew Berens maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $28 to $55.
Leerink Partners analyst Andrew Berens maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $28 to $55.